Skip to content

Efficacy and safety of Albuvirtide plus Lopinavir-ritonavir in HIV-1-infected adults failed standard first-line ART regimen

Efficacy and safety of Albuvirtide plus Lopinavir-ritonavir in HIV-1-infected adults failed standard first-line ART regimen

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004276
Enrollment
Unknown
Registered
2014-02-16
Start date
2014-01-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

Group 1:Albuvirtide once a week + LPV/r
Group 2:LPV/r + TDF+ 3TC

Sponsors

Beijing YouAn Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged 16 to 60 years old; 2. Previously documented HIV infection on standard antibody-based test; 3. Previous antiretroviral therapy (ART) with NRTIs/NNRTIs for more than 6 months; 4. HIV RNA=1000 copies/ml; 5. In good healthy condition by physical examination, biochemistry, hematology and urinalysis test, and electrocardiogram etc., without serious liver and renal damages; 6. Fully understand the purpose, characteristics, procedures of the trial, and the potentially adverse events which might occur during study; willing and able to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute HIV infection,or with AIDS-related disease, such as severe opportunistic infection or tumors; 2. Previously received any protease inhibitors, HIV fusion inhibitors, HIV vaccines, or received other investigational drugs within 3 months; 3. Co-treatment against hepatitis virus; 4. Having abnormal values at screening as follows: Hemoglobin3-fold upper limit of normal value, Total bilirubin >2-fold upper limit of normal value, Creatinine >upper limit of normal value, Creatine phosphokinase >2-fold upper limit of normal value; 5. With allergic constitution, or allergic history of the investigational drug and ART drugs; 6. With serious chronic disease, metabolic disease (such as diabetes), mental disorder and nervous disease; 7. Had a history of hemophilia A or B; 8. Alcohol abuse or drug abuse; 9. Pregnant women, breast feeding women, and women in child-bearing age disagreed with use of birth control; 10. Unsuitable to participate in this study in the opinion of the site investigator.

Design outcomes

Primary

MeasureTime frame
Safety indexes;HIV RNA;

Secondary

MeasureTime frame
CD4 count;

Countries

China

Contacts

Public ContactHao Wu

Beijing YouAn Hospital, Capital Medical University

wuhdoc@public.bta.net.cn+86 010 63053963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026